Results of multivariable Cox proportional-hazards regression analyzing effects of ficolin-3 for all-cause mortality.

*<p>Hazard ratio for ficolin-3 shown as standardized hazard ratio (HR per 1 SD decrease); age was considered as time-dependent covariate.</p>**<p>Wald χ² of likelihood-ratio test.</p

Baseline clinical characteristics according to ficolin-3 levels (median, IQ range, or n (%)).

*<p>p<0.050.</p>**<p>p<0.010.</p>***<p>p<0.001;</p><p>n.d.: not done.</p><p>CAD: coronary artery disease; IDCM: idiopathic dilative cardiomyopathy; NYHA: New York Heart Association; T2DM: Type-2 diabetes mellitus; LVEF: Left-ventricular ejection fraction; CRP: C-reactive protein; NT-proBNP: N-terminal pro-brain natriuretic peptide; ACE-I: angiotensin converting enzyme inhibitor; ASA: Acetyl-salicylic acid; ASAT: aspartate aminotransferase; ALAT: alanin aminotransferase.</p

Univariate correlation of ficolin-3 levels with NT-proBNP (A and B) and complement C3 (C and D).

<p>Pearson’s correlation coefficients and p values are indicated.</p

Kaplan-Meier plot of baseline ficolin-3 levels (<15.0 µg/ml, thick line and > = 15.0 µg/ml, thin line) and long term survival (all-cause mortality) in patients with CHF.

<p>Log-rank test for the Hungarian cohort (panel A) and for the Norwegian cohort (panel B) is indicated.</p

Association of MBL (panels A–B), ficolin-2 (C–D) and ficolin-3 (E–F) levels with severity of CHF.

<p>P values of non-parametric Kruskall-Wallis test are indicated across NYHA class groups, stars indicate results of Dunnet’s post hoc test (*p<0.05, **p<0.01; as compared to NYHA I on panel E and NYHA II on panel F). Medians, 25 and 75 percentiles and ranges are indicated on logarithmic scales.</p